

Eun Ah Choi
Senior Vice President
U.S. Listing Qualifications & Market Surveillance

December 12, 2022

Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Division of Corporation Finance:

This is to certify that on December 12, 2022, The Nasdaq Stock Market LLC (the "Exchange") received from ZyVersa Therapeutics, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b), as amended, for the registration of the following securities:

Common Stock, par value \$0.0001 per share

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking immediate acceleration of the effective registration, and we hereby join in such request.

Sincerely,

